سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Azimi, Behnaz, Kiani, Amir, Noori, Tayebeh, Sureda, Antoni, Shirooie, Samira. (1404). Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathway. , 28(11), 1523-1530. doi: 10.22038/ijbms.2025.87874.18981
Behnaz Azimi; Amir Kiani; Tayebeh Noori; Antoni Sureda; Samira Shirooie. "Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathway". , 28, 11, 1404, 1523-1530. doi: 10.22038/ijbms.2025.87874.18981
Azimi, Behnaz, Kiani, Amir, Noori, Tayebeh, Sureda, Antoni, Shirooie, Samira. (1404). 'Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathway', , 28(11), pp. 1523-1530. doi: 10.22038/ijbms.2025.87874.18981
Azimi, Behnaz, Kiani, Amir, Noori, Tayebeh, Sureda, Antoni, Shirooie, Samira. Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathway. , 1404; 28(11): 1523-1530. doi: 10.22038/ijbms.2025.87874.18981

Silymarin exerts antipsoriatic effects against imiquimod-induced psoriasis in mice via NF-kB/TLR4 signaling pathway

Iranian Journal of Basic Medical Sciences
مقاله 8، دوره 28، شماره 11، بهمن 2025، صفحه 1523-1530    اصل مقاله (474.67 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22038/ijbms.2025.87874.18981
نویسندگان
Behnaz Azimi1؛ Amir Kiani2، 3؛ Tayebeh Noori2؛ Antoni Sureda4، 5؛ Samira Shirooie* 2
1Student Research Committee, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
2Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
3Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
4Research Group on Community Nutrition and Oxidative Stress (NUCOX) and Health Research Institute of Balearic Islands (IdISBa), University of Balearic Islands-IUNICS, Palma de Mallorca E-07122, Balearic Islands, Spain
5CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
چکیده
Objective(s): Psoriasis is an autoimmune disease that mainly affects the skin and joints, which is mediated via T-cells. Several factors contribute to its pathogenesis, including genetic and environmental triggers, as well as intrinsic immune processes that lead to an autoimmune response. Silymarin, a flavonoid complex extracted from Silybum marianum, exhibits anti-inflammatory, immunostimulatory, and anti-oxidant properties, rendering it a viable candidate for treating psoriasis.This study aimed to investigate the effect of silymarin on imiquimod (IMQ) induced psoriasis-like skin lesions in male mice applied as a cream for seven consecutive days (1 mg per mouse).
Materials and Methods: Thirty-five male mice were assigned to seven groups (n=5 per group): (I) control group, (II) IMQ group, (III-V) oral silymarin groups (30, 60, and 120 mg/kg), (VI) topical betamethasone group, and (VII) topical silymarin 2% group. 
Results: Silymarin, both orally and topically, significantly reduces erythema, thickness, and scaling induced by IMQ after seven days of treatment. The treatment also reversed the increase in spleen weight/body weight ratio. Immunofluorescence analysis revealed that silymarin reduced the expression of nuclear factor κB (NF-κB) (P<0.01) and toll-like receptor 4 (TLR4) (P<0.01) compared to the IMQ group.
Conclusion: These findings suggest that silymarin effectively alleviates psoriasis lesions by reducing inflammation and modulating the TLR4/ NF-κB signaling pathway.
کلیدواژه‌ها
Imiquimod؛ Inflammation؛ Male mice؛ Psoriasis؛ Silymarin
مراجع
1. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386:983-994.
2. Schäkel K, Schön MP, Ghoreschi K. Pathogenesis of psoriasis. Hautarzt 2016;67:422-431.
3. Branisteanu DE, Cojocaru C, Diaconu R, Porumb EA, Alexa AI, Nicolescu AC, et al. Update on the etiopathogenesis of psoriasis (Review). Exp Ther Med 2022;23:201-214.
4. Jin Z, Huang Q, Peng J, Liu Z, Hu R, Wu J, et al. MiR-125a-3p alleviates hyperproliferation of keratinocytes and psoriasis-like inflammation by targeting TLR4/NF-κB pathway. Postepy Dermatol Alergol 2023;40:447-461.
5. Lee HJ, Kim M. Challenges and future trends in the treatment of psoriasis. Int J Mol Sci 2023;24:13313.
6. Rujimongkon K, Ampawong S, Reamtong O, Buaban T, Aramwit P. The therapeutic effects of Bombyx mori sericin on rat skin psoriasis through modulated epidermal immunity and attenuated cell proliferation. J Tradit Complement Med 2021;11:587-597.
7. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019; 20:1-12.
8. Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci 2020;21:7488-7503.
9. Kawai T, Akira S. TLR signaling. Semin Immunol 2007;19:24-32.
10. Takeda K, Akira S. Toll-like receptors in innate immunity. Int J Mol Sci 2005;17:1-14.
11. Panzer R, Blobel C, Fölster‐Holst R, Proksch E. TLR 2 and TLR 4 expression in atopic dermatitis, contact dermatitis and psoriasis. Exp Dermatol 2014;23:364-366.
12. Shehata W, Hammam M, Seif D, Elsayed S, Maqsoud E, El-Hefnawy S. Role of Toll-like receptor 4 gene expression in psoriasis and its relation to disease activity. Menoufia Med J 2022;35:418-423.
13. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch 2005;446:475-482.
14. Gaptulbarova KA, Tsyganov MM, Pevzner AM, Ibragimova MK, Litviakov NV. NF-kB as a potential prognostic marker and a candidate for targeted therapy of cancer. Exp Oncol 2020;42:263-269.
15. Moorchung N, Kulaar JS, Chatterjee M, Vasudevan B, Tripathi T, Dutta V. Role of NF-κB in the pathogenesis of psoriasis elucidated by its staining in skin biopsy specimens. Int J Dermatol 2014;53:570-574.
16. Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol 2018;45:264-272.
17. Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF. NF-κB: An essential transcription factor in psoriasis. J Dermatol Sci 2013;69:89-94.
18. van der Fits L, Mourits S, Voerman JSA, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis1. J Immunol 2009;182:5836-5845.
19. Gao J, Chen F, Fang H, Mi J, Qi Q, Yang M. Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice. Biol Res 2020;53:48-60.
20.    Greaves MW, Weinstein GD. Treatment of psoriasis. NEJM 1995;332:581-589.
21. Rahman M, Alam K, Ahmad MZ, Gupta G, Afzal M, Akhter S, et al. Classical to current approach for treatment of psoriasis: A review. Endocr Metab Immune Disord Drug Targets 2012;12:287-302.
22. Rapalli VK, Sharma S, Roy A, Singhvi G. Design and dermatokinetic evaluation of Apremilast loaded nanostructured lipid carriers embedded gel for topical delivery: A potential approach for improved permeation and prolong skin deposition. Colloids Surf. B Biointerfaces 2021;206:111945.
23. Mitra A, Wu Y. Topical delivery for the treatment of psoriasis. Expert Opin Drug Deliv 2010;7:977-992.
24. Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, et al. Psoriasis: Improving adherence to topical therapy. J Am Acad Dermatol 2008;59:1009-1016.
25. Zschocke I, Mrowietz U, Karakasili E, Reich K. Non-adherence and measures to improve adherence in the topical treatment of psoriasis. J Eur Acad Dermatol Venereol 2014;28:4-9.
26. Wadhwa K, Pahwa R, Kumar M, Kumar S, Sharma PC, Singh G, et al. Mechanistic insights into the pharmacological significance of silymarin. Molecules 2022;27:5327-5377.
27. Dobrzynska M, Napierala M, Florek E. Flavonoid nanoparticles: A promising approach for cancer therapy. Biomolecules 2020;10: 1268-1285.
28. Ebrahimi A, Mehrabi M, Miraghaee SS, Mohammadi P, Fatehi Kafash F, Delfani M, et al. Flavonoid compounds and their synergistic effects: Promising approaches for the prevention and treatment of psoriasis with emphasis on keratinocytes – A systematic and mechanistic review. Int Immunopharmacol 2024;138:112561.
29. Alalaiwe A, Lin C-F, Hsiao C-Y, Chen E-L, Lin C-Y, Lien W-C, et al. Development of flavanone and its derivatives as topical agents against psoriasis: The prediction of therapeutic efficiency through skin permeation evaluation and cell-based assay. Int J Pharm 2020;581:119256.
30. Zholobenko A, Modriansky M. Silymarin and its constituents in cardiac preconditioning. Fitoterapia. 2014;97:122-132.
31. Koltai T, Fliegel L. Role of silymarin in cancer treatment: Facts, hypotheses, and questions. J Evid Based Integr Med 2022;27:1-38.
32. Chambers CS, Holečková V, Petrásková L, Biedermann D, Valentová K, Buchta M, et al. The silymarin composition… and why does it matter???. Food Res Int 2017;100:339-353.
33. Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M. “Silymarin”, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci 2011;14:308-317.
34. Comelli MC, Mengs U, Schneider C, Prosdocimi M. Toward the definition of the mechanism of action of silymarin: Activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther 2007;6:120-129.
35. Rostamian S, Heidari-Soureshjani S, Sherwin CMT. The therapeutic effect of silymarin and silibinin on depression and anxiety disorders and possible mechanism in the brain: a systematic review. Cent Nerv Syst Agents Med Chem 2023;23:86-94.
36. Yi M, Manzoor M, Yang M, Zhang H, Wang L, Zhao L, et al. Silymarin targets the FXR protein through microbial metabolite 7-keto-deoxycholic acid to treat MASLD in obese mice. Phytomedicine 2024;133:155947.
37. Piazzini V, D’Ambrosio M, Luceri C, Cinci L, Landucci E, Bilia AR, et al. Formulation of nanomicelles to improve the solubility and the oral absorption of silymarin. Molecules 2019;24:1688-1707.
38. Taleb A, Ahmad KA, Ihsan AU, Qu J, Lin N, Hezam K, et al. Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases. Biomed Pharmacother 2018;102:689-698.
39. Dixit N, Baboota S, Kohli K, Ahmad S, Ali J. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharmacol 2007;39:172-179.
40. Kshirsagar AD, Ingawale DK, Ashok P, Vyawahare NS. Silymarin: A comprehensive review. Phcog Rev 2009;3:116-124.
41. Radko L, Cybulski WA. Application of silymarin in human and animal medicine. J Pre-Clin Res 2007;01:22-26.
42. Tabari SA, Carpi S, Polini B, Nieri P, Esfahani ML, Moghadamnia AA, et al. Topical application of silymarin enhances cutaneous wound healing in rats. S Afr J Bot 2019;124:494-498.
43. Noori T, Sureda A, Shirooie S. Ivermectin decreases inflammation and imiquimod–induced psoriasis-like skin lesions in rat via targeting TLR4/p65 NF-κB. Iran J Basic Med Sci 2025;28:808-814.
44. Guo Y, Wang S, Wang Y, Zhu T. Silymarin improved diet-induced liver damage and insulin resistance by decreasing inflammation in mice. Pharm Biol 2016;54:2995-3000.
45. Stolf AM, Cardoso CC, Acco A. Effects of silymarin on diabetes mellitus complications: A review. Phytother Res 2017;31:366-374.
46. Schäfer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M. Concordance of the psoriasis area and severity index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol 2010;20:62-67.
47. Okasha EF, Bayomy NA, Abdelaziz EZ. Effect of topical application of black seed oil on imiquimod-induced psoriasis-like lesions in the thin skin of adult male albino rats. The Anat Rec 2018;301:166-174.
48. Frenzel DF, Borkner L, Scheurmann J, Singh K, Scharffetter-Kochanek K, Weiss JM. Osteopontin deficiency affects imiquimod-induced psoriasis-like murine skin inflammation and lymphocyte distribution in skin, draining lymph nodes and spleen. Exp Dermatol 2015;24:305-307.
49. Li TY, Liang WL, Zhao YM, Chen WD, Zhu HX, Duan YY, et al. Alpha-Pinene-encapsulated lipid nanoparticles diminished inflammatory responses in THP-1 cells and imiquimod-induced psoriasis-like skin injury and splenomegaly in mice. Front Immunol 2024;15:1390589.
50. Li XP, Liu P, Li YF, Zhang GL, Zeng DS, Liu DL. LPS induces activation of the TLR4 pathway in fibroblasts and promotes skin scar formation through collagen I and TGF-β in skin lesions. Int J Clin Exp Pathol 2019;12:2121-2129.
51. Yao L, Kan EM, Lu J, Hao A, Dheen ST, Kaur C, et al. Toll-like receptor 4 mediates microglial activation and production of inflammatory mediators in neonatal rat brain following hypoxia: Role of TLR4 in hypoxic microglia. J Neuroinflammation 2013;10:785-806.
52. Katiyar SK. Silymarin and skin cancer prevention: Anti-inflammatory, antioxidant and immunomodulatory effects (Review). Int J Oncol 2005;26:169-176.
53. Esmaeil N, Anaraki SB, Gharagozloo M, Moayedi B. Silymarin impacts on immune system as an immunomodulator: One key for many locks. Int Immunopharmacol 2017;50:194-201.
54. Weinstein GD, McCullough JL, Ross PA. Cell kinetic basis for pathophysiology of psoriasis. J Invest Dermatol 1985;85:579-583.
55. Singh RP, Agarwal R. Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal 2002;4:655-663.
56. Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF. NF-κB: an essential transcription factor in psoriasis. J Dermatol Sci 2013;69:89-94.
57. Al-Rasheed NM, Fadda LM, Al-Rasheed NM, Ali HM, Yacoub HI. Down-regulation of NFkB, Bax,TGF-β, Smad-2mRNA expression in the livers of carbon tetrachloride treated rats using different natural antioxidants. Braz Arch Biol Technol 2016;59:1-10.
58. Altindağ F. Silymarin ameliorates cisplatin-induced nephrotoxicity by downregulating TNF-α and NF-kB and by upregulating IL-10. J Exp Clin Med 2022;39:216-220.
59.    He X, Wei Z, Zhou E, Chen L, Kou J, Wang J, et al. Baicalein attenuates inflammatory responses by suppressing TLR4 mediated NF-κB and MAPK signaling pathways in LPS-induced mastitis in mice. Int Immunopharmacol 2015;28:470-476.
60. Linh NTT, Giang NH, Lien NTK, Trang BK, Trang DT, Ngoc NT, et al. Association of PSORS1C3, CARD14 and TLR4 genotypes and haplotypes with psoriasis susceptibility. Genet Mol Biol 2022;45:1-14.
61. Saleh HA, Yousef MH, Abdelnaser A. The anti-inflammatory properties of phytochemicals and their effects on epigenetic mechanisms involved in TLR4/NF-κB-mediated inflammation. Front Immunol 2021;12:1-29.

آمار
تعداد مشاهده مقاله: 601
تعداد دریافت فایل اصل مقاله: 531